NM_001042492.3:c.61-2A>T
Variant summary
Our verdict is Pathogenic. The variant received 10 ACMG points: 10P and 0B. PVS1_ModeratePP5_Very_Strong
The NM_001042492.3(NF1):c.61-2A>T variant causes a splice acceptor, intron change involving the alteration of a conserved nucleotide. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_001042492.3 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Publications
- neurofibromatosis type 1Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, PanelApp Australia, G2P, Genomics England PanelApp
- neurofibromatosis-Noonan syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Genomics England PanelApp, PanelApp Australia
- Moyamoya diseaseInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- hereditary pheochromocytoma-paragangliomaInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- familial ovarian cancerInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 10 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| NF1 | NM_001042492.3 | c.61-2A>T | splice_acceptor_variant, intron_variant | Intron 1 of 57 | ENST00000358273.9 | NP_001035957.1 | ||
| NF1 | NM_000267.4 | c.61-2A>T | splice_acceptor_variant, intron_variant | Intron 1 of 56 | NP_000258.1 | |||
| NF1 | NM_001128147.3 | c.61-2A>T | splice_acceptor_variant, intron_variant | Intron 1 of 14 | NP_001121619.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00 AC: 0AN: 149820Hom.: 0 Cov.: 32
GnomAD2 exomes AF: 0.00000816 AC: 2AN: 244958 AF XY: 0.0000151 show subpopulations
GnomAD4 exome Data not reliable, filtered out with message: AS_VQSR AF: 6.87e-7 AC: 1AN: 1455324Hom.: 0 Cov.: 33 AF XY: 0.00000138 AC XY: 1AN XY: 723944 show subpopulations ⚠️ The allele balance in gnomAD version 4 Exomes is significantly skewed from the expected value of 0.5.
GnomAD4 genome Data not reliable, filtered out with message: AC0;AS_VQSR AF: 0.00 AC: 0AN: 149820Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 72936
ClinVar
Submissions by phenotype
Neurofibromatosis, type 1 Pathogenic:2
- -
For these reasons, this variant has been classified as Pathogenic. This sequence change affects an acceptor splice site in intron 1 of the NF1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in NF1 are known to be pathogenic (PMID: 10712197, 23913538). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. Disruption of this splice site has been observed in individuals with neurofibromatosis type 1 (PMID: 17426081, 22108604). ClinVar contains an entry for this variant (Variation ID: 428979). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.61-2A>T intronic pathogenic mutation results from an A to T substitution two nucleotides upstream from coding exon 2 in the NF1 gene. This mutation has been detected as a germline mutation in a patient with tibial pseudoarthrosis and her father, both of whom hadclinical diagnoses of NF1(Sant D, et al.J. Med. Genet. 2015; 52(4):256-61,PariaN, et al. J. Bone Miner. Res. 2014; 29(12):2636-42).In addition to the clinical data presented in the literature, since alterations that disrupt the canonical splice acceptor site are typically deleterious in nature, this alteration is interpreted asa disease-causing mutation (ACMGRecommendations for Standards for Interpretation and Reporting of Sequence Variations. Revision 2007.Genet Med.2008;10:294). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at